274 related articles for article (PubMed ID: 30833445)
1. A prospective study evaluating the impact of implementing the ERAS protocol on patients undergoing surgery for advanced ovarian cancer.
Agarwal R; Rajanbabu A; P V N; Goel G; Madhusudanan L; U G U
Int J Gynecol Cancer; 2019 Mar; 29(3):605-612. PubMed ID: 30833445
[TBL] [Abstract][Full Text] [Related]
2. PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.
Sánchez-Iglesias JL; Carbonell-Socias M; Pérez-Benavente MA; Monreal Clua S; Manrique-Muñoz S; García Gorriz M; Burgos-Peláez R; Segurola Gurrutxaga H; Pamies Serrano M; Pilar Gutiérrez-Barceló MD; Serrano-Castro S; Balcells-Farré MT; Pérez-Barragán C; Scaillet-Houberechts A; Cossio-Gil Y; Gil-Moreno A
Eur J Cancer; 2020 Sep; 136():149-158. PubMed ID: 32688208
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of an enhanced recovery after surgery (ERAS) pathway in a Norwegian cohort of patients with suspected or advanced ovarian cancer.
Lindemann K; Kleppe A; Eyjólfsdóttir B; Heimisdottir Danbolt S; Wang YY; Heli-Haugestøl AG; Walcott SL; Mjåland O; Navestad GA; Hermanrud S; Juul-Hansen KE; Kongsgaard U
Int J Gynecol Cancer; 2023 Aug; 33(8):1279-1286. PubMed ID: 37451690
[TBL] [Abstract][Full Text] [Related]
4. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
[TBL] [Abstract][Full Text] [Related]
5. Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
Li S; Bercow AS; Falzone M; Kalyanaraman R; Worley MJ; Feltmate CM; Pelletier A; Elias KM
Gynecol Oncol; 2021 Aug; 162(2):353-359. PubMed ID: 34092412
[TBL] [Abstract][Full Text] [Related]
6. Introducing an enhanced recovery after surgery program in colorectal surgery: a single center experience.
Bona S; Molteni M; Rosati R; Elmore U; Bagnoli P; Monzani R; Caravaca M; Montorsi M
World J Gastroenterol; 2014 Dec; 20(46):17578-87. PubMed ID: 25516673
[TBL] [Abstract][Full Text] [Related]
7. Predictive validity of American College of Surgeons: National Surgical Quality Improvement Project risk calculator in patients with ovarian cancer undergoing interval debulking surgery.
Manning-Geist B; Cathcart AM; Sullivan MW; Pelletier A; Cham S; Muto MG; Del Carmen M; Growdon WB; Sisodia RC; Berkowitz R; Worley M
Int J Gynecol Cancer; 2021 Oct; 31(10):1356-1362. PubMed ID: 34518239
[TBL] [Abstract][Full Text] [Related]
8. The impact of Enhanced Recovery after Surgery (ERAS) pathways with regard to perioperative outcome in patients with ovarian cancer.
Reuter S; Woelber L; Trepte CC; Perez D; Zapf A; Cevirme S; Mueller V; Schmalfeldt B; Jaeger A
Arch Gynecol Obstet; 2022 Jul; 306(1):199-207. PubMed ID: 34958401
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported nausea after implementation of an enhanced recovery after surgery protocol for gynae-oncology patients.
Lindemann K; Heimisdottir Danbolt S; Ramberg L; Eyjólfsdóttir B; Wang YY; Heli-Haugestøl AG; Walcott SL; Mjåland O; Navestad GA; Hermanrud S; Juul-Hansen KE; Bragstad LK; Opheim R; Kleppe A; Kongsgaard U
Int J Gynecol Cancer; 2023 Aug; 33(8):1287-1294. PubMed ID: 37451689
[TBL] [Abstract][Full Text] [Related]
10. [Technical essentials and safety analysis of "rolling carpet" cytoreduction surgery in stage Ⅲc epithelial ovarian cancer].
Liu H; Shi Y; Zhang GN; Yu J; Xu SQ; Wang DF; Fan Y; Song SQ; Zhou FZ
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):521-528. PubMed ID: 32854476
[No Abstract] [Full Text] [Related]
11. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
[TBL] [Abstract][Full Text] [Related]
12. Importance of Enhanced Recovery After Surgery (ERAS) Protocol Compliance for Length of Stay in Ovarian Cancer Surgery.
Sánchez-Iglesias JL; Gómez-Hidalgo NR; Pérez-Benavente A; Carbonell-Socias M; Manrique-Muñoz S; Serrano MP; Gutiérrez-Barceló P; Bradbury M; Nelson G; Gil-Moreno A
Ann Surg Oncol; 2021 Dec; 28(13):8979-8986. PubMed ID: 34091804
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcome After Completion Surgery in Patients With Ovarian Cancer: The Charite Experience.
Babayeva A; Braicu EI; Grabowski JP; Gasimli K; Richter R; Muallem MZ; Sehouli J
Int J Gynecol Cancer; 2018 Oct; 28(8):1491-1497. PubMed ID: 30095708
[TBL] [Abstract][Full Text] [Related]
14. Clinical validation and comparison of the Comprehensive Complication Index and Clavien-Dindo classification in predicting post-operative outcomes after cytoreductive surgery in advanced ovarian cancer.
Kengsakul M; Nieuwenhuyzen-de Boer GM; Udomkarnjananun S; Kerr SJ; van Doorn HC; van Beekhuizen HJ
Int J Gynecol Cancer; 2023 Feb; 33(2):263-270. PubMed ID: 36600504
[TBL] [Abstract][Full Text] [Related]
15. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
16. Cost analysis of the enhanced recovery after surgery protocol applied in advanced ovarian cancer: A secondary outcome of the PROFAST trial.
Sánchez-Iglesias JL; Bebia V; Gimenez E; Aller MB; Bradbury M; Pérez-Benavente MA; Gil-Moreno A; Cossio-Gil Y
Eur J Surg Oncol; 2022 Dec; 48(12):2545-2550. PubMed ID: 35922279
[TBL] [Abstract][Full Text] [Related]
17. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery.
Meyer LA; Shi Q; Lasala J; Iniesta MD; Lin HK; Nick AM; Williams L; Sun C; Wang XS; Lu KH; Ramirez PT
Gynecol Oncol; 2019 Mar; 152(3):501-508. PubMed ID: 30876495
[TBL] [Abstract][Full Text] [Related]
18. The KORE-INNOVATION trial, a prospective controlled multi-site clinical study to implement and assess the effects of an innovative peri-operative care pathway for patients with ovarian cancer: rationale, methods and trial design.
Inci MG; Sehouli J; Schnura E; Lee M; Roll S; Reinhold T; Klews J; Kaufner L; Niggemann P; Groeben H; Toelkes J; Reisshauer A; Liebl M; Daehnert E; Zimmermann M; Knappe-Drzikova B; Rolker S; Nunier B; Algharably E; Pirmorady Sehouli A; Zwantleitner L; Krull A; Heitz F; Ataseven B; Chekerov R; Harter P; Schneider S
Int J Gynecol Cancer; 2023 Aug; 33(8):1304-1309. PubMed ID: 37208019
[TBL] [Abstract][Full Text] [Related]
19. Enhanced recovery after surgery protocols improve time to return to intended oncology treatment following interval cytoreductive surgery for advanced gynecologic cancers.
Tankou JI; Foley O; Falzone M; Kalyanaraman R; Elias KM
Int J Gynecol Cancer; 2021 Aug; 31(8):1145-1153. PubMed ID: 33858950
[TBL] [Abstract][Full Text] [Related]
20. The Impact of an Enhanced Recovery After Surgery Program on Patients Treated for Gynecologic Cancer in the Community Hospital Setting.
Mendivil AA; Busch JR; Richards DC; Vittori H; Goldstein BH
Int J Gynecol Cancer; 2018 Mar; 28(3):581-585. PubMed ID: 29466256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
